Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA international affairs (correction)

Executive Summary

VP-International Affairs Geralyn Ritter takes over as head of the Pharmaceutical Research & Manufacturers of America's international affairs group effective immediately. Senior VP-International Affairs Shannon Herzfeld will stay to help with the transition until the end of the year (1"The Pink Sheet" July 12, 2004, In Brief)...

You may also be interested in...



PhRMA international affairs

Pharmaceutical Research & Manufacturers of America Assistant General Counsel Geralyn Ritter will take over leadership of the association's international affairs group as VP-international affairs at the end of 2004. The group said Senior VP-International Affairs Shannon Herzfeld will leave at the end of the year after working with Ritter to ensure a smooth transition. Several PhRMA international affairs executives announced departures recently: former Deputy VP-International Affairs Sean Darragh will join the Biotechnology Industry Organization in August (1"The Pink Sheet" June 28, 2004, In Brief). Associate VP-Europe Line Vreven is also leaving...

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel